Cargando…
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera
BACKGROUND: To investigate a vaccine technology with potential to protect against coronavirus disease 2019 (COVID-19) and reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a single vaccine dose, we developed a SARS-CoV-2 candidate vaccine using the live vesicul...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338221/ https://www.ncbi.nlm.nih.gov/pubmed/35915046 http://dx.doi.org/10.1016/j.ebiom.2022.104203 |
_version_ | 1784759920747347968 |
---|---|
author | Espeseth, Amy S. Yuan, Maoli Citron, Michael Reiserova, Lucia Morrow, Gavin Wilson, Aaron Horton, Melanie Rukhman, Mark Kinek, Keith Hou, Fuxiang Li, Shui L. Li, Fengsheng Choi, Yesle Heidecker, Gwen Luo, Bin Wu, Guoxin Zhang, Lan Strable, Erica DeStefano, Joanne Secore, Susan Mukhopadhyay, Tarit K. Richardson, Douglas D. Sayeed, Eddy Welch, Lisa S. Bett, Andrew J. Feinberg, Mark B. Gupta, Swati B. Cooper, Christopher L. Parks, Christopher L. |
author_facet | Espeseth, Amy S. Yuan, Maoli Citron, Michael Reiserova, Lucia Morrow, Gavin Wilson, Aaron Horton, Melanie Rukhman, Mark Kinek, Keith Hou, Fuxiang Li, Shui L. Li, Fengsheng Choi, Yesle Heidecker, Gwen Luo, Bin Wu, Guoxin Zhang, Lan Strable, Erica DeStefano, Joanne Secore, Susan Mukhopadhyay, Tarit K. Richardson, Douglas D. Sayeed, Eddy Welch, Lisa S. Bett, Andrew J. Feinberg, Mark B. Gupta, Swati B. Cooper, Christopher L. Parks, Christopher L. |
author_sort | Espeseth, Amy S. |
collection | PubMed |
description | BACKGROUND: To investigate a vaccine technology with potential to protect against coronavirus disease 2019 (COVID-19) and reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a single vaccine dose, we developed a SARS-CoV-2 candidate vaccine using the live vesicular stomatitis virus (VSV) chimeric virus approach previously used to develop a licensed Ebola virus vaccine. METHODS: We generated a replication-competent chimeric VSV-SARS-CoV-2 vaccine candidate by replacing the VSV glycoprotein (G) gene with coding sequence for the SARS-CoV-2 Spike glycoprotein (S). Immunogenicity of the lead vaccine candidate (VSV∆G-SARS-CoV-2) was evaluated in cotton rats and golden Syrian hamsters, and protection from SARS-CoV-2 infection also was assessed in hamsters. FINDINGS: VSV∆G-SARS-CoV-2 delivered with a single intramuscular (IM) injection was immunogenic in cotton rats and hamsters and protected hamsters from weight loss following SARS-CoV-2 challenge. When mucosal vaccination was evaluated, cotton rats did not respond to the vaccine, whereas mucosal administration of VSV∆G-SARS-CoV-2 was found to be more immunogenic than IM injection in hamsters and induced immunity that significantly reduced SARS-CoV-2 challenge virus loads in both lung and nasal tissues. INTERPRETATION: VSV∆G-SARS-CoV-2 delivered by IM injection or mucosal administration was immunogenic in golden Syrian hamsters, and both vaccination methods effectively protected the lung from SARS-CoV-2 infection. Hamsters vaccinated by mucosal application of VSV∆G-SARS-CoV-2 also developed immunity that controlled SARS-CoV-2 replication in nasal tissue. FUNDING: The study was funded by Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA. Parts of this research was supported by the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Threat Reduction Agency (DTRA) of the US Department of Defense. |
format | Online Article Text |
id | pubmed-9338221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93382212022-08-01 Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera Espeseth, Amy S. Yuan, Maoli Citron, Michael Reiserova, Lucia Morrow, Gavin Wilson, Aaron Horton, Melanie Rukhman, Mark Kinek, Keith Hou, Fuxiang Li, Shui L. Li, Fengsheng Choi, Yesle Heidecker, Gwen Luo, Bin Wu, Guoxin Zhang, Lan Strable, Erica DeStefano, Joanne Secore, Susan Mukhopadhyay, Tarit K. Richardson, Douglas D. Sayeed, Eddy Welch, Lisa S. Bett, Andrew J. Feinberg, Mark B. Gupta, Swati B. Cooper, Christopher L. Parks, Christopher L. eBioMedicine Articles BACKGROUND: To investigate a vaccine technology with potential to protect against coronavirus disease 2019 (COVID-19) and reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a single vaccine dose, we developed a SARS-CoV-2 candidate vaccine using the live vesicular stomatitis virus (VSV) chimeric virus approach previously used to develop a licensed Ebola virus vaccine. METHODS: We generated a replication-competent chimeric VSV-SARS-CoV-2 vaccine candidate by replacing the VSV glycoprotein (G) gene with coding sequence for the SARS-CoV-2 Spike glycoprotein (S). Immunogenicity of the lead vaccine candidate (VSV∆G-SARS-CoV-2) was evaluated in cotton rats and golden Syrian hamsters, and protection from SARS-CoV-2 infection also was assessed in hamsters. FINDINGS: VSV∆G-SARS-CoV-2 delivered with a single intramuscular (IM) injection was immunogenic in cotton rats and hamsters and protected hamsters from weight loss following SARS-CoV-2 challenge. When mucosal vaccination was evaluated, cotton rats did not respond to the vaccine, whereas mucosal administration of VSV∆G-SARS-CoV-2 was found to be more immunogenic than IM injection in hamsters and induced immunity that significantly reduced SARS-CoV-2 challenge virus loads in both lung and nasal tissues. INTERPRETATION: VSV∆G-SARS-CoV-2 delivered by IM injection or mucosal administration was immunogenic in golden Syrian hamsters, and both vaccination methods effectively protected the lung from SARS-CoV-2 infection. Hamsters vaccinated by mucosal application of VSV∆G-SARS-CoV-2 also developed immunity that controlled SARS-CoV-2 replication in nasal tissue. FUNDING: The study was funded by Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA. Parts of this research was supported by the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Threat Reduction Agency (DTRA) of the US Department of Defense. Elsevier 2022-07-30 /pmc/articles/PMC9338221/ /pubmed/35915046 http://dx.doi.org/10.1016/j.ebiom.2022.104203 Text en © 2022 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA, The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Espeseth, Amy S. Yuan, Maoli Citron, Michael Reiserova, Lucia Morrow, Gavin Wilson, Aaron Horton, Melanie Rukhman, Mark Kinek, Keith Hou, Fuxiang Li, Shui L. Li, Fengsheng Choi, Yesle Heidecker, Gwen Luo, Bin Wu, Guoxin Zhang, Lan Strable, Erica DeStefano, Joanne Secore, Susan Mukhopadhyay, Tarit K. Richardson, Douglas D. Sayeed, Eddy Welch, Lisa S. Bett, Andrew J. Feinberg, Mark B. Gupta, Swati B. Cooper, Christopher L. Parks, Christopher L. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera |
title | Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera |
title_full | Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera |
title_fullStr | Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera |
title_full_unstemmed | Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera |
title_short | Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera |
title_sort | preclinical immunogenicity and efficacy of a candidate covid-19 vaccine based on a vesicular stomatitis virus-sars-cov-2 chimera |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338221/ https://www.ncbi.nlm.nih.gov/pubmed/35915046 http://dx.doi.org/10.1016/j.ebiom.2022.104203 |
work_keys_str_mv | AT espesethamys preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT yuanmaoli preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT citronmichael preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT reiserovalucia preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT morrowgavin preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT wilsonaaron preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT hortonmelanie preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT rukhmanmark preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT kinekkeith preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT houfuxiang preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT lishuil preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT lifengsheng preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT choiyesle preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT heideckergwen preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT luobin preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT wuguoxin preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT zhanglan preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT strableerica preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT destefanojoanne preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT secoresusan preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT mukhopadhyaytaritk preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT richardsondouglasd preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT sayeededdy preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT welchlisas preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT bettandrewj preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT feinbergmarkb preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT guptaswatib preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT cooperchristopherl preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera AT parkschristopherl preclinicalimmunogenicityandefficacyofacandidatecovid19vaccinebasedonavesicularstomatitisvirussarscov2chimera |